Results 101 to 110 of about 898,102 (296)

Combined redifferentiation via HDAC inhibitor and MAPK inhibitor in thyroid cancer cells

open access: yesZhongguo aizheng zazhi, 2017
Background and purpose: Redifferentiation therapy with MAPK inhibitor is a novel strategy for radioiodine-refractory differentiated thyroid cancer, but its efficacy is relatively low.
程凌霄, 靳雨辰
doaj  

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

open access: yesBiotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady   +6 more
wiley   +1 more source

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma

open access: yesJournal of Experimental & Clinical Cancer Research, 2018
Background Glioblastoma (GBM) is the most common and most malignant primary brain cancer in adults. Despite multimodality treatment, the prognosis is still poor.
Wei Meng   +8 more
doaj   +1 more source

DβHB and LβHB do not inhibit HDAC activities.

open access: yes, 2013
Hela nuclear extract was used as a source of class I and II HDAC activity (Panel A) where as recombinant human Sir1 was used as a source of class III HDAC activity (Panel B). HDAC activities were assessed in the absence (control, “C”) or presence of 4 mM
Serge Przedborski (37633)   +6 more
core   +1 more source

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma [PDF]

open access: yes, 2013
Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies ...
Ramos, Juan Carlos   +13 more
core   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

open access: yesBMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen   +9 more
wiley   +1 more source

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia

open access: yesCommunications Biology
KMT2A-rearranged acute lymphoblastic leukemia (ALL) is characterized by deregulation of the epigenome and shows susceptibility towards histone deacetylase (HDAC) inhibition.
Tamara C. A. I. Verbeek   +7 more
doaj   +1 more source

An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation

open access: yes, 2020
The prevention and treatment of malaria requires a multi-pronged approach, including the development of drugs that have novel modes of action. Histone deacetylases (HDACs), enzymes involved in post-translational protein modification, are potential new ...
Hesping, Eva   +4 more
core   +1 more source

Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment [PDF]

open access: yes, 2016
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis.

core   +1 more source

Home - About - Disclaimer - Privacy